ras homolog family member VGenealiases: ARHV · CHP · WRCH2
Q-omics provides the consensus-scored RHOV profile across patient tissues and cancer cell-line models. RHOV expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RHOV is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, RHOV RNA expression shows 14,945 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LUAD, THCA, and ESCA as cancer lineages where RHOV shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHOV — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHOV survival associations across molecular data types. RHOV RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHOV RNA expression–survival associations across cancer types. High RHOV expression shows unfavorable associations in LUAD, UVM, ACC, COAD, PAAD and SKCM. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RHOV RNA expression.
This table summarizes RHOV tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RHOV. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHOV shows lower tumor expression in KIRC and KIRP and higher tumor expression in THCA, LUAD, LUSC and BLCA. The THCA box plot shows higher RHOV RNA expression in tumor versus normal tissue (log2 FC = +2.194, t-test p < 0.001).
This table shows molecular features associated with RHOV in patient tissues and cancer cell lines. In patient samples, RHOV shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RHOV RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
